NCT04628780View on ClinicalTrials.gov

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

May 3, 2023

Study Completion Date

May 26, 2023

Conditions
Non-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaUrothelial CarcinomaColorectal CarcinomaOvarian Carcinoma
Interventions
BIOLOGICAL

PF-07209960

PD-1 targeted IL-15 mutein

Trial Locations (13)

37203

Tennessee Oncology PLLC, Nashville

The Sarah Cannon Research Institute/Tennessee Oncology, Nashville

TriStar Centennial Medical Center, Nashville

77030

The University of Texas MD Anderson Cancer Center- Investigational Pharmacy, Houston

The University of Texas MD Anderson Cancer Center, Houston

78229

Christus Santa Rosa Hospital, San Antonio

NEXT Oncology, San Antonio

90095

Ronald Reagan UCLA Medical Center, Los Angeles

UCLA Hematology/Oncology, Los Angeles

90404

Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica

UCLA Hematology Oncology - Santa Monica, Santa Monica

91010

City of Hope Investigational Drug Service (IDS), Duarte

City of Hope, Duarte

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04628780 - Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter